Guidelines for the role of FDG-PET/CT in lung cancer management

Journal of Infection and Public Health

Volumn 5, Issue 5 SUPPL.1, 2012, Pages

  AL Jahdali, Hamdan ^a   Khan, Ali Nawaz ^b   Loutfi, Shukri ^a   Al Harbi, Abdullah S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cancer; CT; FDG PET; Guidelines; Lung; PET; Saudi

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LUNG NODULE; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SMALL CELL LUNG CARCINOMA;

EID: 84870949746     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2012.09.003     Document Type: Article

References (35)

1. Christensen J.A., Nathan M.A., Mullan B.P., Hartman T.E., Swensen S.J., Lowe V.J. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. American Journal of Roentgenology 2006, 187(November (5)):1361-1367.
2. Fletcher J.W., Kymes S.M., Gould M., Alazraki N., Coleman R.E., Lowe V.J., et al. Cooperative Studies Group. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. Journal of Nuclear Medicine 2008, 49(February (2)):179-185. [Epub 2008 January 16].
3. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285:914-924.
4. Fischer B., Lassen U., Mortensen J., Larsen S., Loft A., Bertelsen A., et al. Preoperative staging of lung cancer with combined PET-CT. New England Journal of Medicine 2009, 361(1):32-39. [Erratum in: New England Journal of Medicine 2011 March 10;364(10):982].
5. Dwamena B.A., Sonnad S.S., Angobaldo J.O., Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology 1999, 213:530-536.
6. Dwamena M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Annals of Internal Medicine 2003, 139:879-892.
7. Silvestri G.A., Gould M.K., Margolis M.L., et al. Noninvasive staging of non-small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest 2007, 132(3 Suppl.):178S-201S.
8. Tournoy K.G., Maddens S., Gosselin R., Van Maele G., Van Meerbeeck J.P., Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007, 62:696-701.
9. Alberts W.M. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest 2007, 132(3 Suppl.):1S-19S.
10. Pieterman R.M., van Putten J.W.G., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. New England Journal of Medicine 2000, 343:254-261.
11. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2001, 50:287-293.
12. Hicks R., Kalff V., MacManus M., et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. Journal of Nuclear Medicine 2001, 42:1596-1604.
13. Sachs S., Bilfinger T.V. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005, 128:698-703.
14. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery 2003, 126:1943-1951.
15. van Tinteren H., Hoekstra O., Smit E., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS Multicentre Randomised Trial. Lancet 2002, 359:1388-1393.
16. Detterbeck F.C., Jantz M.A., Wallace M., et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest 2007, 132(3 Suppl.):202S-220S.
17. De Leyn P., Lardinois D., Van Schil P.E., et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 2007, 32:1-8.
18. Fischer B.M., Mortensen J., Langer S.W., Loft A., Berthelsen A.K., Petersen B.I., et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Annals of Oncology 2007, 18(February (2)):338-345. [Epub 2006 October 23].
19. Grégoire V., Haustermans K., Geets X., et al. PET-based treatment planning in radiotherapy: a new standard?. Journal of Nuclear Medicine 2007, 48:68S-77S.
20. Greco C., Rosenzweig K., Cascini G.L., Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer. Lung Cancer 2007, 57:125-134.
21. Grgic A., Nestle U., Schaefer-Schuler A., Kremp S., Kirsch C.M., Hellwig D. FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning-an intraindividual comparison. International Journal of Radiation Oncology, Biology, Physics 2009, 73(1):103-111. [Epub 2008 July 14].
22. Berman A.T., Rengan R. New approaches to radiotherapy as definitive treatment for inoperable lung cancer. Seminars in Thoracic and Cardiovascular Surgery 2008, 20:188-197.
23. Ceresoli G.L., Cattaneo G.M., Castellone P., Rizzos G., Landoni C., Gregorc V., et al. Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation. Tumori 2007, 93(January-February (1)):88-96.
24. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. Journal of Clinical Oncology 2003, 21:1285-1292.
25. Vansteenkiste J., Fischer B.M., Dooms C., Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncology 2004, 5:531-540.
26. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., Oven W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007, 110:1654-1664.
27. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. Journal of Clinical Oncology 2003, 21:2651-2657.
28. Berghmans T., Dusart M., Paesmans M., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Journal of Thoracic Oncology 2008, 3:6-12.
29. Tann M., Sandrasegaran S., Winer-Muram H.T., et al. Can 18F-FDG-PET be used to predict growth of stage I lung cancer?. Clinical Radiology 2008, 63:856-863.
30. Goodgame B., Pillot G.A., Yang Z., et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. Journal of Thoracic Oncology 2008, 3:130-134.
31. Huang W., Zhou T., Ma L., Sun H., Gong H., Wang J., et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38(September (9)):1628-1635. [Epub 2011 May 27].
32. De Wever W., Stroobants S., Coolen J., Verschakelen J.A. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. European Respiratory Journal 2009, 33:201-212.
33. Hwangbo B., Kim S.K., Lee H.S., Lee H.S., Kim M.S., Lee J.M., et al. Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. Chest 2009, 135:1280-1287.
34. De Leyn P., Stroobants S., De Wever W., Lerut T., Coosemans W., Decker G., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease alter induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. Journal of Clinical Oncology 2006, 24:3333-3339.
35. Sánchez de Cos J., Hernández J.H., López M.F., Sánchez S.P., Gratacós A.R., Porta R.R. SEPAR guidelines for lung cancer staging. Archivos de Bronconeumologia 2011, 47(September (9)):454-465. [Epub 2011 August 6].